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Abstract: Significant progression has been achieved in the treatment of metastatic colorectal 
cancer (mCRC) in recent years. This has been partly attributed to successfully incorporating 
new drugs into combination chemotherapy. In addition to the traditional cytotoxic chemothera-
peutic agents, molecularly targeted agents began to play an important role in the treatment of 
advanced solid tumors. To date, two classes of molecularly targeted agents have been approved 
for treatment of patients with mCRC: (1) antivascular endothelial growth factor (anti-VEGF) 
agents (such as bevacizumab and aflibercept) and (2) antiendothelial cell growth factor recep-
tor (anti-EGFR) agents (such as cetuximab and panitumumab). Aflibercept is a new member 
of anti-VEGF agents which has demonstrated efficacy for treatment of mCRC. With the com-
mencement of clinical trials and basic research into aflibercept, more data from the bedside and 
the bench have been obtained. This review will outline the application of anti-VEGF agents by 
reviewing clinic experiences of bevacizumab and aflibercept, and try to add perspectives on 
the use of anti-VEGF agents in mCRC.
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Introduction
Colorectal cancer (CRC) is a critical health problem. With more than 800,000 new 
cases diagnosed every year, CRC is the third most-common cancer worldwide.1 
Although mortality from CRC has decreased slightly over the past decade as a result 
of earlier diagnosis, approximately 20% of patients advance to metastatic disease.2 
When it comes to the stage where it cannot be surgically removed, the prognosis of 
this disease is poor.
Rapid advances in tumor biology are promising a new era of molecularly targeted 
cancer therapy. Bevacizumab is a monoclonal antibody targeted at vascular endothelial 
growth factor (VEGF). By preventing VEGF binding to their receptors (VEGFRs), it 
can inhibit tumor angiogenesis. A phase III trial revealed that the overall survival was 
extended from 15.6 months to 20.3 months (P , 0.001) when bevacizumab was added 
to irinotecan plus fluorouracil/leucovorin (IFL) for treatment of metastatic colorectal 
cancer patients (mCRC).3 The results have been promising and have assisted in the 
mechanisms of tumor angiogenesis being further understood,4,5 with more than 50 new 
drugs with anti-angiogenic activity having been developed.6
Recently, aflibercept (VEGF-Trap), a fusion protein with high VEGF affinity, has 
extended progression-free survival and overall survival of mCRC patients in a phase III 
trial (VELOUR),7 which included aflibercept with irinotecan/5-FU as second-line 
chemotherapy.
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Anti-VEGF rationale for mCRC
Neovascularization is a critical process in solid tumor 
  progression. Without vascular provided oxygen and nutrients, 
tumors struggle to grow beyond 2 mm in diameter.8,9
Blood vessel formation in tumors involves several 
  different processes: the classic endothelial sprouting 
process, vessel co-option, intussusceptive microvascular 
growth (IMG), glomeruloid angiogenesis, endothelial 
progenitor cell mobilization, and vasculogenic mimicry.5 
In most conditions, new vascular blood flows were formed 
by endothelial-sprouting from existing vessels, called 
  angiogenesis. Neovascularization is regulated by the bal-
ance of pro- and anti-angiogenic factors.4,10 VEGF family 
members are believed to be the most important proangio-
genic   factors. VEGF-A is thought to be the key controller 
of the angiogenic switch.11,12 VEGF promotes angiogenesis 
by stimulating endothelial cell proliferation and migration, 
altering blood vessel permeability, and controlling the func-
tional and morphological form of these vessels.
Further, VEGF can play a role in the non-sprouting 
vascularization processes previously mentioned.5,13 For 
example, it can recruit marrow-derived circulating endothe-
lial cell progenitors (CEPs) to create vascular formations. 
In tumors, VEGF-induced vessels are structurally imma-
ture and functionally abnormal, which is characterized by 
irregular dilated lumina, tortuous shape, pericyte deficiency, 
and hyper permeability.10 This abnormal vasculature leads 
to increased interstitial fluid pressure (IFP), as well as 
deficiency of nutrients and oxygen delivery, which triggers 
further VEGF production.14 High IFP can further hinder 
the delivery of nutrients and oxygen, as well as cytotoxic 
drugs.15 Studies have revealed that VEGF expression is 
elevated in a wide variety of tumor types including CRC.16,17 
Hyper expression of VEGF has also been demonstrated to 
be associated with the progression, invasion, and metastasis 
of CRC.16,18
VEGF is considered a key target for treatment of solid 
tumors and this idea has been proven by bevacizumab, which 
is a humanized monoclonal antibody against VEGF-A. 
  Validated by testing in various animal models, antiangiogenic 
drugs (including anti-VEGF agents) work via several mecha-
nisms, such as increasing the delivery of cytotoxic drugs via 
vessel normalization.19 An additional hypothesis is that anti-
angiogenic drugs can control tumor cell repopulation during 
the chemotherapy drug-free break period. A third hypothesis 
is that inhibiting the mobilization of marrow derived circulat-
ing endothelial cells (CECs) or their progenitors (CEPs) is 
an important mechanism for antiangiogenic drugs to slow 
tumor growth and sensitize chemotherapy.20,21
Clinical evidence of anti-VEGF 
strategy in mCRC treatment
Bevacizumab is the most clinically advanced anti-VEGF agent 
and the first one to receive approval for first- and second-line 
treatment of mCRC. The experience of bevacizumab is indica-
tive of the value of anti-VEGF strategies in the treatment of 
CRC. Clinical experience of anti-VEGF treatment of mCRC 
provided by bevacizumab was reported as follows:
1.	 As a single agent, it only provided modest response rates 
but demonstrated significant efficacy when combined 
with other strategies.22
2.	 It demonstrated efficacy in combination with all the basic 
chemotherapeutic regimens, but failed to provide benefits 
in combination with anti-EGFR agents.
3.	 More and more evidence suggests that continuous admin-
istration can provide survival benefits, even after disease 
progression.
4.	 Application in postoperative adjuvant therapy is not 
advisable as there is no efficacy at increasing overall 
survival.
After the pivotal trial proved that it can prolong overall 
survival, bevacizumab has been extensively incorporated 
into various chemotherapy protocols to manage mCRC. The 
most commonly used first-line chemotherapy regimens for 
CRC in clinical practice (FOLFOX [LV , 5-FU, oxaliplatin], 
FOLFIRI [LV , 5-FU, irinotecan], and XELOX [capecitabine, 
oxaliplatin]),23 have all been proven to benefit from the com-
bination with bevacizumab (Table 1).
Combination with irinotecan  
contained regimen
Combined bevacizumab with irinotecan contained regimen 
IFL was verified firstly in the phase III trial which led to the 
approval of bevacizumab in the treatment of mCRC. The 
bolus IFL regimen, which was proven later in the BICC-C 
trial to be inferior, had increased toxicity and less efficacy24 
and was replaced by the infusion regimen FOLFIRI. It is this 
trial also that proved the superior clinical activity of FOLFIRI 
over a modified IFL (mIFL) regimen with prolonged median 
progression-free survival (PFS) (7.6 versus 5.9 months). More-
over, median overall survival (OS) was significantly prolonged 
for the FOLFIRI plus bevacizumab group, compared with 
the mIFL plus bevacizumab group (median OS 28.0 versus 
19.2 months; P = 0.037).25
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Combination with oxaliplatin-based 
regimen
When bevacizumab was incorporated into the oxalipla-
tin-based regimen, bevacizumab failed to increase response 
rates (38% in both arms) or survival (19.9 months versus 
21.3 months, P = 0.077, compared with either combination 
alone) of metastasis mCRC, with either FOLFOX or XELOX 
in N016966 trial. This may be caused by frequent disruption, 
as “on treatment” PFS benefit is significant.26 In the following 
Eastern Cooperative Oncology Group trial (ECOG 3200), the 
use of bevacizumab with FOLFOX in second-line treatment of 
metastatic colon cancer resulted in significantly improved PFS 
(7.3 months versus 4.7 months) and median survival (12.9 months 
versus 10.8 months) compared with FOLFOX alone.27
Combination with 5-FU-based regimen
As there are some patients that can’t receive multi-drug 
  chemotherapy due to tolerance problems or other reasons, 
they may be treated with single 5-Fu. A combined analysis of 
the results from three different studies showed that the com-
bination with bevacizumab is superior to 5-FU alone.28,29
Continued application in refractory 
disease
The nonrandomized prospective observational study, BRiTE 
(Bevacizumab Regimens: investigation of Treatment Effects 
and safety), firstly evaluated the efficacy of bevacizumab in the 
post-progressive treatment for mCRC. Results showed that it 
provided significant efficacy and appropriate safety. The OS 
from the time of progression for the group that received post-
progressive therapy with the bevacizumab containing regimen 
was 19.2 months, while it was 9.5 months for the group that 
received post-progressive therapy without bevacizumab.30,31 
Samelis et al32 recently reported on 21 patients included in 
their retrospective study results, in which bevacizumab was 
continuously applied on these mCRC patients, who had 
received at least one course of irinotecan-based or oxaliplatin-
based chemotherapy with bevacizumab, after disease progres-
sion: the median OS was 23+ months, and median time to 
progression (TTP) was 17 months.
Combination with EGFR inhibitor
Two classes of targeted agent have been validated in the 
treatment of mCRC in combination with chemotherapy: 
anti-VEGF agent and EGFR inhibitor. Of note, there were 
studies that indicated that EGFR had a potent effect on tumor-
associated angiogenesis and combined treatment with EGFR 
and VEGF signaling inhibitors had at least additive antitumor 
activity.15,33,34 The use of dual biologic therapies in combina-
tion with cytotoxic chemotherapy has been evaluated by two 
phase II studies, the PACCE and CAIRO 2. H  owever, the 
results are only of impaired benefits and increased toxicity.35,36 
Table 1 Critical trials of bevacizumab for metastatic colorectal cancer
Basic chemotherapy Clinic trial (references) Bevacizumab schedule Median PFS Median OS
Irinotecan
iFL AVF21073 5 mg/kg iV, every 2 weeks 10.6 vs 6.2 months,  
P , 0.001
20.3 vs 15.6 months, P , 0.001
FOLFiRi or miFL BiCC-C24,25,a FOLFiRi+Bev: 5 mg/kg iV,  
every 2 weeks; 
miFL+Bev: 7.5 mg/kg iV,  
every 3 weeks
7.6 vs 5.9 months 23.1 vs 17.6 months  
(without Bev); 28.0 vs  
19.2 months (with Bev)
Oxaliplatin
FOLFOX or XELOX NO1696626,b 7.5 mg/kg iV, every 3 weeks 9.4 vs 8.0 months,  
P = 0.0023
21.3 vs 19.9 months; P = 0.077
FOLFOX4 E320027 10 mg/kg iV, every 14 days 7.2 vs 4.8 months;  
P , 0.0001
12.5 vs 10.7 months; P = 0.0024




FOLFOX and bFOL:  
5 mg/kg iV, every 2 weeks; 
CapeOx: 7.5 mg/kg iV,  
every 3 weeks
8.7, 6.9, and 5.9 vs  
9.9, 8.3, and 10.3 months
19.2, 17.9, and 17.2 vs 26.1,  
20.4, and 24.6 months
5-FU
5-FU/LV AVF0780, AVF2107  
and AVF219228,29,d
5 mg/kg iV, every 2 weeks 8.8 vs 5.6 months,  
P # 0.001
17.9 vs 14.6 months, P = 0.008
Notes: aPrimary aim was to compare FOLFiRi with miFL; bThe “on treatment” PFS benefit is larger; cThey are two independent trials, without comparison directly; dit’s a 
combined analysis of the three trials.
Abbreviations: IV, intravenous; Bev, bevacizumab; mIFL, modified IFL.
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The results are further supported by the recently reported 
Phase III trial, which compared the treatment of mFOL-
FOX6-B (modified FOLFOX6 + bevacizumab) with that of 
FOLF-CB (5-FU, leucovorin, + bevacizumab and cetuximab) 
for CRC patients. The results revealed that the efficacy of 
the dual biologic FOLF-CB group was not superior to the 
mFOLFOX6-B group. Patient satisfaction favored the control 
(mFOLFOX6-B).37 Twelve-month PFS was 45% versus 32%, 
and median OS was 21 months versus 19.5 months.
Application in postoperative adjuvant 
therapy
Experimental evidence suggests that VEGF induced 
  vasculogenesis is most important in the earlier stage of 
  tumorigenesis and progression. Consequently, anti-VEGF 
agents provide their greatest benefit early in disease when 
tumors are small and there is minimal residual disease.15 Thus, 
it is a good choice to use bevacizumab in the   adjuvant setting 
in principle. However, there is little further evidence that 
encourages us going forward because of the   disappointing 
results of two phase III trials in postoperative chemotherapy 
(NSABP C-08 and AVANT).38,39
Characteristics and application 
information of aflibercept
Aflibercept is a fully human recombinant protein which is 
constructed by fusing the second extracellular domain of 
VEGFR1 and the third extracellular domain of VEGFR2 to 
the Fc segment of immunoglobulin G1.40 Other than bevaci-
zumab and ranibizumab binding all isomers of the VEGF-A, 
aflibercept also binds VEGF-B and placental growth factor.41,42 
Early studies in murine models revealed that aflibercept can 
bind with very high affinity (≈1 pM) to multiple isoforms of 
VEGF, which was superior to other anti-VEGF reagents.43 
Being studied on various animal model, aflibercept has been 
proven to act on endothelial cells, pericytes, and even the vas-
cular basement membrane or VEGF receptor, resulting in the 
inhibition of new vessel growth and remodeling of preexisting 
ones, which had been detected in bevacizumab.43,44 Remodel 
effects usually present as the normalization of tumor vascu-
lature, which is believed to be the mechanism of anti-VEGF 
agents enhancing chemotherapy efficacy.45
As we detailed earlier,44 in mouse model studies,   aflibercept 
can decrease vascular growth and density, and suppress tumor 
growth, when combined with HER2 antibodies (trastuzumab) 
to treat breast carcinoma; enhance the efficacy of radiation 
for treating neuroblastoma xenografts; reduce tumor burden; 
and inhibit metastasis of ovarian cancer in combination with 
paclitaxel.46 Completed phase I trials suggest that aflibercept 
is well tolerated and the advised dose is 4 mg/kg.44,47 The 
most common drug toxicities reported in phase I/II trials 
include fatigue, proteinuria, hypertension, nausea, and 
lymphopenia.48–50 Grade 3 to 4 toxicity incidence is extremely 
rare. It’s notable that thromboembolic events are less observed, 
which are frequent in treatment with   bevacizumab. If this dif-
ference is real, it may be attributed to the 1:1 bind ratio with 
VEGF and full human protein sequences.51
Since anti-VEGF monotherapy showed poor results in 
previous trials, anti-VEGF treatment is often combined with 
other strategies. Most of the phase II and III trials evaluated 
aflibercept efficacy in combination with chemotherapy. To 
date, a range of tumor types have been treated with aflibercept 
in clinical trials, including ovarian cancer, non-small cell lung 
adenocarcinoma, prostate carcinoma, and mCRC.41,52
One Phase III trial (VELOUR) is evaluating aflibercept 
as a second line treatment for mCRC in combination with 
  FOLFIRI. In total, 1226 patients with mCRC received 
FOLFIRI and either aflibercept (4 mg/kg) or a placebo 
every 2 weeks after failure of one oxaliplatin-based therapy. 
PFS was 6.90 months versus 4.67 months (hazard ratio 
[HR] 0.758, P = 0.00007) and objective response rate 
(ORR) 19.8% versus 11.1% (P = 0.0001). Median OS was 
13.50 months for aflibercept arm and 12.06 months for placebo 
arm (HR 0.817, P = 0.0032). T  reatment discontinuation for 
adverse events occurred in 26.6% and 12.1% in aflibercept 
arm and placebo arm, respectively.7
Recently, at the Deutsche Bank BioFEST conference, 
the preliminary results of the Phase II trial (AFFIRM), in 
which aflibercept was used with modified FOLFOX6 as 
first line treatment for patients with mCRC, has been dis-
closed. It showed that the PFS rate at 1 year, for patients 
who received aflibercept in combination with mFOLFOX6, 
was similar to that seen in the standard therapy arm for 
patients who received mFOLFOX6 alone. The toxicity pro-
file of aflibercept was similar to what has been seen in prior 
  trials with aflibercept and consistent with other anti-VEGF 
agents. The full data set should be available at future medical 
  conferences.53 With these proofs, Regeneron’s collaborator, 
Sanofi (Paris, France), has submitted a Biologics License 
Application to the US Food and Drug Administration for 
marketing approval of ZALTRAP™ (aflibercept) for second 
line treatment of mCRC.
There is an ongoing regional phase I trial, in which 
aflibercept is intravenously administered in combina-
tion with FOLFIRI for Japanese patients with metastatic 
colorectal cancer. The primary objective is to determine the 
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dose of aflibercept to be further studied in combination with 
FOLFIRI in Japanese patients.54
Questions and further investigations
It’s great news that a new tool is being added to the arsenal 
for us to fight against mCRC. However, aflibercept may 
encounter a similar problem to bevacizumab in clinical 
application. Even though earlier promising data suggested 
that aflibercept has a much higher VEGF binding affinity 
than bevacizumab, more clinical data is needed to prove that 
it can be more effective.
The first issue is that VEGF induced vasculogenesis is 
mostly important in the earlier stage in tumorigenesis and 
progression.15 Based on this rationale, anti-VEGF agents are 
expected to provide better disease control in the adjuvant 
s  etting. Paradoxically, clinical data concluded that incor-
porating the anti-VEGF agent bevacizumab into adjuvant 
regimens does not prolong disease-free survival (DFS) or 
OS of patients with CRC.38,39 Thus, to make aflibercept and 
other anti-VEGF agents exert greater action, the effect of 
VEGF and the anti-VEGF results in tumor vasculogenesis 
or development need to be further investigated.
Based on the theory of vascular normalization, anti-VEGF 
agents should be used to provide a “normalization window” 
for chemotherapeutic drugs. That means anti-VEGF agents 
should be administered intermittently, to avoid hindering the 
delivery of chemotherapeutic drugs. However, there is evi-
dence showing benefits of continuous or prolonged use, even 
after disease progression.55,56 This is not consistent with the 
hypothesis that continuous treatment with bevacizumab may 
stimulate some alternative proangiogenic signals that induce 
resistance to it.14,57 Aflibercept studies should also answer the 
question of whether anti-VEGF agents should be continu-
ously given in the full schedule of mCRC treatment.
Both anti-VEGF agents and EGFR inhibitors have dem-
onstrated efficacy for the treatment of mCRC and crossover 
effects were observed between EGFR and VEGF signals.33,34 
However, the dual biologic therapy in combination with che-
motherapeutic regimens failed to demonstrate effectiveness 
in the PACCE and CAIRO 2 study.35,36 indicating that dual 
aflibercept and anti-EGFR therapy should not be used in com-
bination with cytotoxic chemotherapy as a routine treatment 
in the front-line setting. We are expecting the results of an 
alternative combination in a phase III study, which combined 
chemotherapy and bevacizumab with or without erlotinib to 
treat patients with metastatic colorectal cancer (that cannot 
be removed by surgery).58 Alternative combinations can also 
be considered for other protocols or drugs, for example, 
metronomic chemotherapy (MCT) or vascular disrupting 
agents (VDA), both of which target blood vessels in tumors, 
with the effect on CEPs.59,60 A combination of the two with 
anti-VEGF agents may be suitable for mCRC. What’s more, 
sequential or alternate use of them and anti-VEGF drugs may 
avoid resistance induced by a single agent.
It is clear the benefit varied when bevacizumab was tested 
in different trials. This may have been caused by drugs or regi-
mens that are more appropriately combined with anti-VEGF 
agents or caused by different patient’s genetic backgrounds. 
Unfortunately, to date, there is no validated biomarker that can 
be used to select patients.61 Plasma angiogenic molecules, such 
as VEGF, placenta growth factor (PIGF), soluble VEGFR-2, 
and basic fibroblast growth factor (bFGF) were most often 
studied for their significant level-change during the bevaci-
zumab application,62 but hitherto, none of them have been 
proven to be of predictive value. In recent years, viable CECs 
and CEPs (which play an important role in tumor angiogen-
esis) have frequently been studied. Prior studies have revealed 
anti-angiogenic agents have potential inhibitory effects on 
mobilization or proliferation of endothelial progenitor cells 
(EPCs) in tumor tissue and CEC and CEP numbers have the 
potential to become surrogate biomarkers for predicting and 
monitoring drug activity.63 Therefore, clarifying the mecha-
nism of EPCs in angiogenesis will facilitate the application 
of bevacizumab, aflibercept, and other anti-VEGF agents. 
Conversely, clinically confirming whether there are some 
drugs or regimens that are more suitable for combination with 
anti-VEGF agents is another urgent task.
Conclusion
As anti-VEGF agents, aflibercept and bevacizumab are 
promising drugs with the potential to prolong the life of 
patients with mCRC but there are quite a few problems that 
need to be resolved before they significantly change the 
outcome of mCRC. To this end, there is still a long way to 
go in antiangiogenesis therapy-related basic, clinical, and 
translational studies.
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